Compromising PPARγ/RXRα function through RNAi and pharmacological inhibition enhanced expression of immune-potentiating chemokines in bladder cancer cells bearing RXRαS427F/Y or overexpressing PPARγ, offering the initial steps toward reprogramming the cancer immunity and restoring response to immunotherapies (Fig. 5e–g). Here, RXRA is linked to urinary bladder carcinoma.